Argenica Therapeutics Advances Phase 2 Stroke Trial
Company Announcements

Argenica Therapeutics Advances Phase 2 Stroke Trial

Argenica Therapeutics Ltd (AU:AGN) has released an update.

Argenica Therapeutics Ltd has received a positive safety review from the independent Data Safety Monitoring Board for its Phase 2 trial of ARG-007 in stroke patients, with no serious adverse events reported. The trial is progressing well, with 63% of patient dosing completed across activated hospital sites. The company anticipates full dosing completion by mid-2025, with topline data expected shortly after.

For further insights into AU:AGN stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App